Search 

license-in paradigm shifting durgs to China patients

Libera Bio develops a new family of cancer treatments based on its patented actively targeted delivery technology to intracellular targets (MPN – Multifunctional Polymeric Nanocapsules) and on novel monoclonal antibodies (e.g. anti KRAS), with the goal to have them commercialized by large biopharma companies after regulatory approval for clinical trials or early proof-of-concept in humans.

Libera Bio lead candidate aims at providing a new treatment for those highly prevalent and aggressive cancers which are driven by KRAS mutations, such as pancreatic cancer, lung cancer and colorectal cancer.

Lilly

Link Health is a leading Chinese pharmaceutical company based in Southern China, focusing on the development of innovative drugs for the unmet medical needs.
Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, favourable regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently.
The company has established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office focuses on collaborations with global pharma/biotech partners and research institutes.

LinkedUp Bio, pioneered a novel antibody drug discovery engine that is dedicated to developing novel biological therapeutics for diseases that have limited or no successful treatment.
The gamechanger element is that we can scree the entire natural immune repertoire with unprecedented speed and scales and identified hits rapidly and efficiently, thereby greatly increasing the success rate of potential therapeutics for targets that are hard to drug.

AbLink Platform: Screening the entire immune repertoire for more efficient antibody discovery
LInkedUp Bio is using microfluidic device to enable single B cell encapsulation, and subsequently, extract the information of heavy chain and light chain of antibody from tens of millions of B cells and then transferred them into our in-house engineered yeast system. These antibody copies in the yeast cells maintained their natural heavy chaiin and light chain pair, and good biophysical stabilities of the original B cells. Our yeast strain has both display and secretion mode which enables quick chacterization of the potential hits, eliminating the step for mamamlian expression for further hits validation, a typical bottleneck for many single B cell platfrom.

The AbLink Platform is the only platform allowing comprehensive screening of the natural antibody repertoire. This results in at least 100 times more hits than hybridoma and other single B cell platforms. Other benefits include more extensive epitope coverage, more unique and rare sequences & diversity, higher affinity, and functionality. Currently the platform gathered a great deal of interest in industry as we already collaborated with two biopharmas and several others are in the middle of conversation.

LUB-001 : Tackling malignant melanoma and solid tumors
LinkedUp Bio’s first target indication is malignant melanoma, one of the deadliest forms of human cancer, due to the high incidence of metastases and drug resistance. Extensive research supports the role of a new target X for malignant melanoma, potentially affecting tumor growth, survival and metastasis. However, due to the limitations of traditional antibody discovery technologies and the complex structure of the target, there have been numerous antibody candidates that showed limited efficacy in inhibition of tumor growth, never matched the high expectation and promise of a breakthrough treatment.
LinkedUp developed a novel antibody clone for this target X and in vitro data demonstrated drastically improvement of the ability of the immune system to attack the tumor cells. LinkedUp Bio’s approach can provide a novel promising treatment for many different types of cancer, such as triple negative breast cancer, glioblastoma, hepatocellular carcinoma, and more.
LUB-002: Tackling congenital muscular dystrophy
Alpha Dystrolycanopathy is a clinically and genetically heterogeneous group of muscular dystrophies with the defective matriglycan which links the muscle cells with extracellular matrix . The cause of the defection involved more than 18 genes, and manifested various degree of severity in clinical symptoms. Currently there no effective therapy for this group of diseases. Novel strategies like antisense, AAV gene therapy, enzyme replace can only address one kind gene a time, making a significant commercial challenge. We propose a novel bispecific antibody approach that functions as a surrogate molecular linker to reconnect extracelluar matrix and the muscle cells to ameliorate sarcolemmal fragility, a primary pathology in patients with alpha-dystroglycan- related muscular dystrophies.

We are currently seeking fund to move our program forward and expand our team.

Team:
Greg Li, Co-founder, President
Stephen Gillies, Co-founder, CSO
Tao Wang, Co-founder, Vice President of Antibody Discovery

Jason Lavinder, Cofounder, Advisory Board

Links global business. One hub for the Middle East

We are focused on regenerative therapy technology R&D since 2002.

UK based VC investing in life-sciences technology, tools and drug platforms. Other areas of interest include digital therapeutics.